Drugs / Allogeneic Mesenchymal Stromal Cells
Allogeneic Mesenchymal Stromal Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05286255 | Oct 2024 | viral pneumonia | Medical University of South Carolina | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02421484 | May 2015 → Jun 2016 | infectious disease with sepsis | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04626583 Comparator | Mar 2021 → Apr 2023 | corneal disorder | University of Illinois at Chicago | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Mesenchymal Stromal Cells | “Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells” NCT04626583 ↗ |
| Known as | mesenchymal stem (stromal) cells | “In septic animal models mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance tissue repair and pathogen clearance, and reduce death.” PMID 28960096 ↗ Feb 2018 |
| Known as | MSC | “In septic animal models mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance tissue repair and pathogen clearance, and reduce death.” PMID 28960096 ↗ Feb 2018 |
| Known as | MSCs | “In septic animal models mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance tissue repair and pathogen clearance, and reduce death.” PMID 28960096 ↗ Feb 20181“allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias” NCT05286255 ↗ |
| Known as | UC-MSCs | “Allogeneic UC-MSCs given intravenously at 1.2-1.5 x 106 cells/kg on day 1 and day 3 of study entry” NCT05286255 ↗ |
| Modality | Cell therapy | “The infusion of freshly cultured allogenic bone marrow-derived MSCs, up to a dose of 3 million cells/kg (250 million cells), into participants with septic shock seems safe.” PMID 28960096 ↗ Feb 2018 |
| Route | Intravenous | “The allogeneic mesenchymal stromal cells will be administered intravenously.” NCT02421484 ↗ |